- Wang H, Li X, Li T, Zhang S, Wang L, Wu X, et al.. The genetic sequence, origin, and diagnosis of SARS-CoV-2. 2020;39(9):1629-35.
- WHO SAJWHO. WHO coronavirus disease (COVID-19) dashboard. 2020.
- Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 2020 Sep;61(3):E304-e12.
- Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression. Physiology (Bethesda). 2020 Sep 1;35(5):288-301.
- Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M, Szpirt W, et al.. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11(1):316-29.
- Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clinical Immunology. 2020 2020/06/01/;215:108448.
- Cauchois R, Koubi M, Delarbre D, Manet C, Carvelli J, Blasco VB, et al.. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):18951-3.
- Klinger JM, Ravarani CNJ, Bannard C, Lamparter M, Schwinges A, Cope JL, et al.. Critically ill COVID-19 status associated trait genetics reveals CDK6 inhibitors as potential treatment. 2021.
- Ochsner SA, Pillich RT, McKenna NJ. Consensus transcriptional regulatory networks of coronavirus-infected human cells. Sci Data. 2020 Sep 22;7(1):314.
- Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J Med Virol. 2020 Oct;92(10):2105-13.
- Na-Bangchang K, Porasuphatana S, Karbwang J. Perspective: repurposed drugs for COVID-19. Arch Med Sci. 2022;18(5):1378-91.
- Ghafoor K, Özcan M, Al Juhaimi F, Babiker E, Sarker MZ, Mohamed Ahmed I, et al.. Nutritional Composition, Extraction and Utilization of Wheat Germ Oil: A Review. European Journal of Lipid Science and Technology. 2016 12/01;119.
- Panel CJHN, editor: In. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2020.
- Elwakil B, Shaaban M, Bekhit A, El-Naggar M, Olama Z. Potential anti-COVID-19 activity of Egyptian propolis using computational modeling. Future Virology. 2021 02/01.
- Sands JA. Inactivation and inhibition of replication of the enveloped bacteriophage phi6 by fatty acids. Antimicrobial agents and chemotherapy. 1977 1977/10//;12(4):523-8.
- A, Arafat RA. Ameliorative Effect of Wheat Germ Oil in Potassium bromate Induced Biochemical and Histopathological Changes in Male Rat's Heart. International Journal of Pharmaceutical And Phytopharmacological Research. 2019;9(5):126-31.
- Aziza S, Hussein S, Abdel-Aal SA, Elghwab AIM. Biochemical role of wheat germ oil on biomarkers of oxidative stress and inflammatory response in a rat model of endotoxemia. BENHA VETERINARY MEDICAL JOURNAL. 2014 12/01;27:157‐67.
- Yousuf M, Shamsi A, Queen A, Shahbaaz M, Khan P, Hussain A, et al.. Targeting cyclin-dependent kinase 6 by vanillin inhibits proliferation of breast and lung cancer cells: Combined computational and biochemical studies. J Cell Biochem. 2021 Aug;122(8):897-910.
- Peng Y, Liu L, Wang Y, Yao J, Jin F, Tao T, et al.. Treatment with toll-like receptor 2 inhibitor ortho-vanillin alleviates lipopolysaccharide-induced acute kidney injury in mice. Exp Ther Med. 2019 Dec;18(6):4829-37.
- Arya S, Rookes J, Cahill D, Lenka S. Vanillin: a review on the therapeutic prospects of a popular flavouring molecule. Advances in Traditional Medicine. 2021 01/07;21.
- Mai CW, Kang YB, Hamzah AS, Pichika MR. Comparative efficacy of vanilloids in inhibiting toll-like receptor-4 (TLR-4)/myeloid differentiation factor (MD-2) homodimerisation. Food Funct. 2018 Jun 20;9(6):3344-50.
- Masoud H, Elassal G, Zaky S, Baki A, Ibrahem H, Amin W, et al.. Management Protocol for COVID-19 Patients Version 1.4/30th May 2020 Ministry of health and population (MOHP), Egypt. 2020.
- Food, Administration D. Assessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment, 2020. 2021.
- Inoue H. Overview of Automated Hematology Analyzer XE-2100™. Sysmex Journal International. 1999;9(1; SEAS SUM):58-64.
- Scharnhorst V, Noordzij PG, Lutz A, Graser U, Püntener D, Alquézar-Arbé A. A multicenter evaluation of a point of care CRP Test. Clin Biochem. 2019;71:38-45.
- World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama. 2013 Nov 27;310(20):2191-4.
- WHO Guidelines Approved by the Guidelines Review Committee. Therapeutics and COVID-19: living guideline. Geneva: World Health Organization © World Health Organization 2021.; 2022.
- Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al.. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist. 2018 Aug;23(8):943-7.
- World Health Organization. Research guidelines for evaluating the safety and efficacy of herbal medicines:. WHO Regional Office for the Western Pacific. 1993.
- World Health Organization. Guidelines for the assessment of herbal medicines. World Health Organization. 1991.
- Calixto JB. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Braz J Med Biol Res. 2000;33:179–89.
- Egyptian Drug Authority. Egyptian Guidelines for Registration of Herbal Medicines: Egyptian Drug Authority, Central Administration for Pharmaceutical products; 2021.
- Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al.. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International Journal of Infectious Diseases. 2021;103:214-6.
- Reis G, Silva EASM, Silva DCM, Thabane L, Milagres AC, Ferreira TS, et al.. Effect of Early Treatment with Ivermectin among Patients with Covid-19. 2022;386(18):1721-31.
- Kariyawasam JC, Jayarajah U, Riza R, Abeysuriya V, Seneviratne SL. Gastrointestinal manifestations in COVID-19. Trans R Soc Trop Med Hyg. 2021 Dec 2;115(12):1362-88.
|